Park Medi World Ltd (PARKHOSPS) Q1 FY27 Results Analysis: PAT Jumps 42%, EBITDA Margin Contracts 115 bps
Cofacto Research
Updated August 03, 2026
2 min read
Positive
Park Medi World Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 475.71 Cr (+19.27% YoY) and PAT growth of +35.23% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | August 03, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 475.71 Cr (+19.27% YoY) |
|---|
| PAT (Q1) | Rs. 88.59 Cr (+35.23% YoY) |
|---|
| EBITDA margin | 26.51% (+20 bps YoY) |
|---|
| EPS (Q1) | Rs. 2.05 (+20.59% YoY) |
|---|
| Market cap | Rs. 12,692.16 Cr |
|---|
| CMP | Rs. 294.60 |
|---|
Quarter Snapshot
Revenue grew 19.3% YoY with PAT to owners up 42.3% YoY, and PAT margin of 18.62% exceeded the guided range. However, EBITDA margin contracted 115 bps QoQ due to Panchkula ramp-up, and near-term margin pressure from new hospital additions is expected. The company remains on track for its FY27 margin guidance.
Key Investment Insights
Key Positives
- Revenue grew 19.3% YoY to Rs.475.71 Cr, fifth consecutive quarter of double-digit growth.
- PAT attributable to owners grew 42.3% YoY to Rs.82.51 Cr.
- PAT margin of 18.62% exceeded the guided range of 15-17%.
- Finance costs declined 35.2% YoY to Rs.9.81 Cr due to near-debt-free balance sheet.
- Material costs as a percentage of revenue improved 133 bps YoY.
- New bed capacity expanded from ~3,610 to ~3,960 with Panchkula commissioning.
Risk Factors
- EBITDA margin contracted 115 bps QoQ to 26.51% due to Panchkula initial ramp-up drag.
- New hospital ramp-up (Panchkula, upcoming Rudrapur, Zirakpur) expected to keep margins in lower half of guided band near term.
- Other expenses as a percentage of revenue rose 39 bps YoY.
- Effective tax rate dropped to 15.69% due to deferred tax benefit of Rs.9.34 Cr, which may not recur.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings
Login Now